Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis

Figures & data

Table 1 Patient Characteristics

	Total	q3 Weeks Carboplatin	Weekly Carboplatin
Overall (n)	76	29	47
Completed ≥90% of planned doses of carboplatin	65	26 (90%)	39 (83%)
Age – median (range)	49 (25–76)	48 (48–68)	47 (25–76)
Receptor Status (n)
ER <1%	69	28	41
ER 1–10%	7	1	6
Clinical Nodal Status (n)
Lymph node negative	41	18	23
Lymph node positive	35	11	24
Clinical Stage (n)
Operable (stage I–IIIA)	69	42	27
Stage I (T1N0)	6	3	3
Stage IIA (T1N1/T2N0)	36	21	15
Stage IIB (T2N1/T3N0)	21	13	8
Stage IIIA (T2N2/T3N1)	6	5	1
Inoperable (stage IIIB-C)	7	5	2
Genetic Testing (n)
Testing performed	63	22	41
BRCA 1 or 2 negative	54	18	36
BRCA 1 or 2 positive	9	4	5
Weekly Paclitaxel Dosing (n)
Received >90% of planned doses	61/68 (90%)	19/21 (90%)	42/47 (89%)
Received ≤ 90% doses	7/68 (10%)	2/21 (10%)	5/47 (11%)
Median post-op follow-up (range)	18 months (<1–118)	53 months (0–118)	13.5 months (<1–51)

Table 2 Pathologic Complete Response (pCR)* Rates by Every 3-Weeks versus Weekly Dosing of Carboplatin

	Total	q3 Weeks Carboplatin	Weekly Carboplatin
Participants (n)	76	29	47
Overall [95% CI]	41 (54%) [42–65%]	16 (55%) [36–74%]	25 (53%) [38–68%]
Subgroup Analysis
Operable disease	39/69 (57%)	16/27 (59%)	23/42 (54.8%)
Inoperable disease	2/7 (29%)	0/2 (0%)	2/5 (40%)
Received >90% doses of weekly paclitaxel	32/61 (52%)	10/19 (53%)	22/42 (53%)
Received ≤90% doses of weekly paclitaxel	4/7 (57%)	1 /2 (50%)	3/5 (60%)
Relapse free survival	64/76 (84%)	26/29 (90%)	38/47 (81%)

Note: *pCR as defined by ypT0/isN0.

Table 3 Variations of Carboplatin Dosing in Neoadjuvant Treatment of Breast Cancer and Reported pCR Rates

	Regimen	n	q3 Weeks Carboplatin pCR Rate	Weekly Carboplatin pCR Rate
CALGB 40603	q3Cb + wP→ AC ± Bev	221	54%
BrighTNess	q3Cb + wP → AC	160	58%
	q3Cb + wP + veliparib → AC	316	53%
KEYNOTE 522	q3Cb + wP → AC/EC	84	56%
	wCb + wP → AC/EC	116		48%
GeparSixto	wCb + wP + lipoA + Bev	158		64%
UVMCC+WIHRI cohorts	q3Cb + wP → AC	29	55%
	wCb + wP → AC	47		52%

Abbreviations: q3Cb, every 3-week carboplatin; wCb, weekly carboplatin; wP, weekly paclitaxel; AC, doxorubicin and cyclophosphamide; EC, epirubicin and cyclophosphamide; lipoA, nonpegylated liposomal doxorubicin; bev, bevacizumab.